Balchem Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCPC research report →
Range $210 – $215
Price Chart
About the company
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
- CEO
- Theodore L. Harris
- IPO
- 1986
- Employees
- 1,430
- HQ
- Montvale, NJ, US
Get TickerSpark's AI analysis on BCPC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.20B
- P/E
- 31.00
- Fwd P/E
- 29.84
- PEG
- 1.93
- P/S
- 4.74
- P/B
- 4.00
- EV/EBITDA
- 19.40
- Div Yield
- 0.58%
- Gross Margin
- 36.46%
- Op Margin
- 21.40%
- Net Margin
- 15.41%
- ROE
- 13.21%
- ROIC
- 11.92%
Latest fiscal year · YoY change
- Revenue
- $1.04B+8.8%
- Gross Profit
- $370.63M+10.2%
- Op Income
- $218.33M
- Net Income
- $154.84M+20.5%
- EPS
- $4.80+20.9%
- OCF Growth
- +19.0%
- FCF Growth
- +18.3%
- 52W High
- $186.15
- 52W Low
- $147.18
- 50D MA
- $169.82
- 200D MA
- $169.61
- Beta
- 0.85
- RSI (14)
- 39
- Avg Volume
- 250.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Balchem posted record third-quarter sales, earnings, and EBITDA on broad-based growth across all three segments, and management said it remains confident in continued year-over-year growth into Q4 despite normal seasonal softness.· October 23, 2026
- Record consolidated revenue of $291 million rose 8.6% year over year, with record GAAP net income of $47 million and diluted EPS of $1.46, up 16% and 17.7%, respectively.
- Adjusted EBITDA reached a record $80 million, up 12.4%, while adjusted EPS was $1.57, up 16.3%.
- Gross margin expanded to $106 million, or 36.4% of sales, up 70 basis points, helped by higher sales, favorable mix, and manufacturing efficiencies.
- All three segments grew: Human Nutrition and Health sales were $188 million, Animal Nutrition and Health $63 million, and Specialty Products $37 million.
- Management highlighted strong cash generation, $58 million of free cash flow, $66 million of cash, $28 million of share repurchases, and net leverage of 0.2x.
- The company reiterated optimism for Q4, saying it is usually seasonally lower than Q3 but expects continued year-over-year growth.
Balchem reported record third-quarter consolidated revenue of $291 million, up 8.6% year over year. Gross margin was $106 million, up 10.7%, and gross margin as a percentage of sales expanded 70 basis points to 36.4%. GAAP earnings from operations were a record $62 million, up 14.4%; GAAP net income was a record $47 million, up 16%; and diluted EPS was $1.46, up 17.7%. On an adjusted basis, EBITDA was a record $80 million, up 12.4%; adjusted net income was a record $50 million, up 14.5%; and adjusted diluted EPS was $1.57, up 16.3%. Cash from operations was $70 million, free cash flow was $58 million, and the quarter ended with $66 million of cash. Looking ahead, management said Q4 is normally sequentially lower than Q3 because of seasonality, but it expects healthy year-over-year growth to continue; no specific quarterly numeric guidance was provided.
CEO Ted Harris said the quarter reflected healthy broad-based growth across all three segments and continued execution on strategic growth initiatives. He emphasized the company’s “unique portfolio” of specialty nutrients and delivery systems, favorable better-for-you consumer trends, and a positive demand outlook across human nutrition, animal nutrition, and specialty products. He also spent time on the newly published VitaCholine and K2VITAL studies, framing them as additions to Balchem’s science-backed ingredient story and as support for future marketing efforts.
CFO Martin Bengtsson said margins benefited from a favorable mix shift, with higher-margin nutrition within Human Nutrition and Health growing faster than food, and higher-margin ruminant business growing faster within Animal Nutrition and Health. He said raw-material inflation remained present, but the company was able to pass it through, leaving it roughly breakeven year to date on an input-cost basis, though timing differences created some quarter-to-quarter noise. He also highlighted strong cash generation, $28 million of stock repurchases, $28 million of net borrowings paid down, a net leverage ratio of 0.2x, and a newly expanded $650 million credit facility that supports innovation, capacity expansion, and acquisitions.
Analysts focused on margin sustainability, the two newly published science studies, ANH growth drivers, inventory, and future scientific/marketing initiatives. Management said margin tailwinds come from portfolio mix as higher-margin nutrition and ruminant businesses outgrow lower-margin areas, while inflation is being passed through. On the science front, management said the VitaCholine and K2VITAL studies are important but still early, and the next step is to build customer awareness through marketing rather than make a product-specific clinical leap immediately. On inventory, Bengtsson said the $177 million balance reflects inflation, growth, safety stock for risk mitigation, and buildup ahead of product launches.
The bullish case is that Balchem is showing durable broad-based growth, with records in revenue, earnings, EBITDA, and cash flow, plus 29 consecutive quarters of year-over-year adjusted EBITDA growth. Management described demand as healthy across human nutrition, animal nutrition, and specialty products, and sees added upside from science-driven differentiation in VitaCholine and K2VITAL. The balance sheet is also strong, with low leverage and capacity to fund growth investments and acquisitions.
The main risks raised were seasonality, continued inflation in raw materials, and ongoing competitive/trade issues in animal nutrition, especially circumvention and pricing pressure in Europe and the potential for similar issues in the U.S. Management also said Q4 is normally sequentially lower than Q3, even if year-over-year growth is expected to continue. In addition, the inventory build suggests more capital is being tied up for risk mitigation and launches, and management acknowledged that higher oil prices would likely be a net negative because they raise transportation and input costs while not meaningfully reviving the fracking-related business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 31.78M
- Float Shares
- 31.60M
of shares held by institutions
424 13F filers
Congressional trading
Senate and House stock disclosures for BCPC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Sep 17, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jul 10, 26 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Apr 9, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 2, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | May 21, 20 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
| Thomas Roland TillisSenate · NC | Sell | Feb 13, 15 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.90M | ▼ 64.50K |
| Vanguard Group Inc | 3.88M | ▼ 17.38K |
| Vanguard Portfolio Management LLC | 2.19M | ▼ 26.39K |
| Vanguard Capital Management LLC | 1.44M | ▼ 5.90K |
| State Street Corp | 1.28M | ▼ 4.80K |
| Geode Capital Management, LLC | 1.12M | ▲ 1.54K |
| Conestoga Capital Advisors, LLC | 854.55K | ▼ 233.32K |
| Morgan Stanley | 851.80K | ▲ 17.36K |
| Dimensional Fund Advisors LP | 638.63K | ▲ 28.58K |
| Wasatch Advisors LP | 630.44K | ▼ 420.34K |
| First Trust Advisors LP | 611.59K | ▼ 5.64K |
| Geneva Capital Management LLC | 603.56K | ▼ 79.54K |
Held by 462 ETFs
Biggest fund positions in BCPC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Gonzalez Ren Anthony | other | 0 |
| Sep 16, 26 | Gonzalez Ren Anthony | other | 0 |
| Feb 8, 27 | Gonzalez Ren Anthony | other | 0 |
| Apr 1, 26 | Gilson Erin Leigh | other | 0 |
| Dec 22, 21 | Gilson Erin Leigh | other | 0 |
| Feb 13, 20 | Gilson Erin Leigh | other | 0 |
| Feb 13, 21 | Gilson Erin Leigh | other | 0 |
| Feb 8, 24 | Gilson Erin Leigh | other | 0 |
| Feb 8, 25 | Gilson Erin Leigh | other | 0 |
| Feb 11, 22 | Gilson Erin Leigh | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BCPC coverage
Recent articles, reports, and earnings notes.
No research on BCPC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCPC report →Balchem: Solid Q3 Performance Support Buy Rating
seekingalpha.com · Nov 5
Balchem Corporation to Participate in Baird's Global Industrial Conference on November 11, 2026
globenewswire.com · Oct 28
3 Companies With Room to Pass on Costs to Manage Inflation
marketbeat.com · Oct 26
Balchem: Record Sales, Great Fundamentals, Priced Fully, Hold
seekingalpha.com · Oct 24
Balchem: 3 Key Takeaways for Long-Term Investors
fool.com · Oct 23
Balchem Corporation (BCPC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 23
Balchem Corporation Reports Third Quarter 2026 Financial Results
globenewswire.com · Oct 23
Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026
globenewswire.com · Oct 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.